RxDoctor Payments Data

Xinyan Hu, PA

Physician Assistant · Glendale, CANPI 1508522426

Payments from drug & device makers

$6,451in general payments, 2019–2025

Across 230 payments — averaging $28.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • AbbVie$1K
  • Incyte Corporation$741
  • Galderma Laboratories, L.p.$459
  • Amgen$428
  • E.r. Squibb & Sons, L.L.C.$412
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$6,03794%
  • Education$4146%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,451 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$13,768
Medicare patients
43
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZoryveRoflumilast11$9,244
Tacrolimus25$3,779
Ketoconazole157$2,307
Clobetasol Propionate26$1,484
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc21$1,295
Tretinoin18$1,214
Metronidazole15$792
Triamcinolone Acetonide82$786
Fluocinonide11$614
Ammonium Lactate23$580
Imiquimod17$530
Clotrimazole15$492
Clindamycin Phosphate12$455
Mupirocin67$357
Hydrocortisone42$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$263$9,24411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →